$RLMD News

Full Transcript: Relmada Therapeutics Q2 2026 Earnings Call

Relmada: 'Hold' Based On Needed NVD-01 Manufacturing Push For IND YE2026 And Sepranolone Advancement

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Relmada Therapeutics Q2 EPS $(0.11) Beats $(0.20) Estimate

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Relmada Therapeutics Joins Russell 2000 Index And Russell 3000 Index

Relmada: NDV-01 Entering Phase 3 In NMIBC, But There's No Rush To Buy Stock Today

Relmada Therapeutics (RLMD): 10 Best Growth Stocks Under $30 to Buy Now

Relmada's Cancer Drug Candidate Sparks Fresh Bullish Call

HC Wainwright & Co. Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $12

Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program